Eli Lilly and Company (NYSE:LLY) has a beta value of 0.34 and has seen 2,518,889 shares traded in the recent trading session. The company, currently valued at $177.77 Billion, closed the recent trade at $185.63 per share which meant it gained $6.83 on the day or 3.82% during that session. The LLY stock price is -1.98% off its 52-week high price of $189.3 and 36.94% above the 52-week low of $117.06. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.88 Million shares traded. The 3-month trading volume is 4.18 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The consensus among analysts is that Eli Lilly and Company (LLY) is an Overweight stock at the moment, with a recommendation rating of 2.2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 7 out of 18 have rated it as a Hold, with 11 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $2.35.

Eli Lilly and Company (NYSE:LLY) trade information

Sporting 3.82% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Jan 11 when the LLY stock price touched $189.3 or saw a rise of 2.07%. Year-to-date, Eli Lilly and Company shares have moved 9.8%, while the 5-day performance has seen it change 12.82%. Over the past 30 days, the shares of Eli Lilly and Company (NYSE:LLY) have changed 15.84%. Short interest in the company has seen 5.2 Million shares shorted with days to cover at 1.24.

Wall Street analysts have a consensus price target for the stock at $188.6, which means that the shares’ value could jump 1.6% from current levels. The projected low price target is $150 while the price target rests at a high of $227. In that case, then, we find that the latest price level in today’s session is +22.29% off the targeted high while a plunge would see the stock lose -19.19% from current levels.

Eli Lilly and Company (LLY) estimates and forecasts

Figures show that Eli Lilly and Company shares have outperformed across the wider relevant industry. The company’s shares have gained +9.1% over the past 6 months, with this year growth rate of 24.34%, compared to 11.1% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 35.8% and 13.1% for the next quarter. Revenue growth from the last financial year stood is estimated to be +9.3%.

12 analysts offering their estimates for the company have set an average revenue estimate of $7.28 Billion for the current quarter. 3 have an estimated revenue figure of $6.66 Billion for the next quarter concluding in March 01, 2021. Year-ago sales stood $6.11 Billion and $5.86 Billion respectively for this quarter and the next, and analysts expect sales will grow by 19.1% for the current quarter and 13.7% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +17.4% over the past 5 years. Earnings growth for 2021 is a modest +54.1% while over the next 5 years, the company’s earnings are expected to increase by 13.66%.

LLY Dividends

Eli Lilly and Company is expected to release its next earnings report between January 29 and January 29 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 3.4 at a share yield of 1.9%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 2.3%.

Eli Lilly and Company (NYSE:LLY)’s Major holders

Insiders own 0.16% of the company shares, while shares held by institutions stand at 79.17% with a share float percentage of 79.3%. Investors are also buoyed by the number of investors in a company, with Eli Lilly and Company having a total of 2304 institutions that hold shares in the company. The top two institutional holders are Lilly Endowment, Inc with over 111.13 Million shares worth more than $16.45 Billion. As of September 29, 2020, Lilly Endowment, Inc held 11.62% of shares outstanding.

The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 69.17 Million shares as of September 29, 2020. The firm’s total holdings are worth over $10.24 Billion and represent 7.23% of shares outstanding.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard/Primecap Fund. As of September 29, 2020, the former fund manager holds about 2.52% shares in the company for having 24140930 shares of worth $3.57 Billion while later fund manager owns 21.23 Million shares of worth $3.14 Billion as of September 29, 2020, which makes it owner of about 2.22% of company’s outstanding stock.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on..

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free


Please enter your comment!
Please enter your name here